<%server.execute "isdev.asp"%> Pediatric N-methyl-<sc>d</sc>-aspartate receptor autoimmune encephalitis Uvais N A - J Pediatr Neurosci
home : about us : ahead of print : current issue : archives search instructions : subscriptionLogin 
Users online: 253      Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
  Table of Contents    
LETTER TO EDITOR
Year : 2018  |  Volume : 13  |  Issue : 1  |  Page : 122-123
 

Pediatric N-methyl-d-aspartate receptor autoimmune encephalitis


Department of Psychiatry, IQRAA International Hospital and Research Centre, Calicut, Kerala, India

Date of Web Publication16-May-2018

Correspondence Address:
Dr. N A Uvais
Department of Psychiatry, IQRAA International Hospital and Research Centre, Calicut, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JPN.JPN_153_17

Rights and Permissions

 



How to cite this article:
Uvais N A. Pediatric N-methyl-d-aspartate receptor autoimmune encephalitis. J Pediatr Neurosci 2018;13:122-3

How to cite this URL:
Uvais N A. Pediatric N-methyl-d-aspartate receptor autoimmune encephalitis. J Pediatr Neurosci [serial online] 2018 [cited 2019 Oct 19];13:122-3. Available from: http://www.pediatricneurosciences.com/text.asp?2018/13/1/122/232432




Dear Sir,

I have read the review on “Pediatric autoimmune encephalitis,” with interest.[1]N-methyl-d-aspartate receptor (NMDAR) encephalitis, a newly discovered autoimmune encephalitis with auto-antibodies that target neuronal surface or synaptic antigens, has been identified as a frequent cause of encephalitis among pediatric population.[1] Through this letter, we tried to highlight some recently available information about this disease in pediatric population.

As authors pointed out, anti-NMDAR encephalitis presents with a variety of neuropsychiatric symptoms.[1] A recent case series from a teaching hospital in India reported clinical details of 21 cases from 2010 to 2016, of which 16 were girls, with mean age of the sample between 10 and 11 years. Interestingly, all the children had psychiatric symptoms at clinical presentation, and 47% had it as the first symptom. Mainly mood symptoms such as inappropriate crying, social withdrawal, unprovoked anger outbursts, and unprovoked screaming were reported. Hallucinations, fearfulness, hyperactivity, violence, and inappropriate laughing were infrequently reported. Furthermore, 52.4% of the sample was diagnosed with a psychiatric disorder according to International Classification of Diseases-10: organic mood disorder, organic hallucinosis, organic catatonic disorder, and obsessive compulsive disorder. Majority of the children also had seizures and movement disorder at clinical presentation.[2]

The diagnosis of anti-NMDAR encephalitis requires identification of the antibodies in cerebrospinal fluid and/or serum. Electroencephalogram (EEG) and magnetic resonance imaging (MRI) of the brain are also commonly used to support the diagnosis.[1] The aforementioned case series reported abnormal EEG in 18 children and abnormal MRI of the brain in 8 children.[2]

The role of functional MRI in understanding and diagnosing adult anti-NMDAR encephalitis has been highlighted by a recent study, where authors used structural and resting-state functional MRI to investigate alterations in connectivity in patients with anti-NMDAR encephalitis. The study results showed widespread alterations of functional connectivity even in patients with a normal structural MRI, which correlated with clinical measures. Memory impairment was found to correlate with hippocampal and medial temporal lobe network connectivity, and schizophrenia-like symptoms were correlated with functional connectivity changes in frontoparietal networks. Furthermore, the study identified frontoparietal and frontotemporal connections as reliably discriminating features between patients and controls, yielding an overall accuracy of 81%.[3]

Authors mentioned the association of ovarian teratoma with anti-NMDAR encephalitis. However, in pediatric population, the comorbidity of ovarian teratoma was less frequently found. A past study reported that only ~6% girls younger than 12 years with anti-NMDAR encephalitis had a tumor.[4] In the aforementioned case series from India, none of the patients had a comorbid ovarian teratoma.[2]

The treatment of anti-NMDAR encephalitis includes high-dose corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange as first-line therapy, and rituximab and/or cyclophosphamide as second-line therapy. In the aforementioned case series from India, all the patients were initially treated with high-dose corticosteroids (30mg/kg/day intravenous infusion for more than 4–5h for 5 days). Thirteen patients needed additional immune modulation (nine received plasmapheresis and four received IVIg). No patient received any second-line therapy, indicating the effectiveness of immunotherapy in pediatric anti-NMDAR encephalitis.[2]

The authors mentioned low efficacy of antipsychotics in controlling psychiatric symptoms and advocated sedative and sleep medications other than benzodiazepines for the same. However, in the aforementioned recent case series from India, 13 children (61.9%) required psychotropic medications for the management of psychiatric symptoms, of which mostly prescribed medications were atypical antipsychotics (quetiapine, risperidone, and olanzapine) and benzodiazepines (clonazepam and lorazepam).[2]

In conclusion, pediatric anti-NMDAR encephalitis is a challenging clinical situation for diagnosis and management, with good prognosis. However, we need further studies in identifying specific neuropsychiatric symptoms in pediatric population, which could be different from adult population. The recent case series highlighted mood-related neuropsychiatric symptomatology in pediatric anti-NMDAR encephalitis. It will be interesting to see functional connectivity abnormalities in functional MRI in pediatric anti-NMDAR encephalitis in comparison to adult anti-NMDAR encephalitis. Furthermore, there is an urgent need of a guideline for the pharmacological management of psychiatric symptoms in pediatric anti-NMDAR encephalitis, which often differ from center to center.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric autoimmune encephalitis. J Pediatr Neurosci 2017;13:130-4.  Back to cited text no. 1
    
2.
Basheer S, Nagappa M, Mahadevan A, Bindu PS, Taly AB, Girimaji SC. Neuropsychiatric manifestations of pediatric NMDA receptor autoimmune encephalitis: A case series from a tertiary care center in India. Prim Care Companion CNS Disord 2017;13. pii: 17m02110. doi: 10.4088/PCC. 17m02110.  Back to cited text no. 2
    
3.
Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: An observational study. Lancet Psychiatry 2017;13:768-74.  Back to cited text no. 3
    
4.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;13:157-65.  Back to cited text no. 4
    




 

Top
Print this article  Email this article
 
 
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (180 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed354    
    Printed10    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal